Oculis Holding AG
OCS • Biotechnology
$7.49
▲ +0.17 (+2.32%)
Current price
EarningsLatest report: Mar 31, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$440.02M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.01Healthy liquidity · 5.96Weak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 11, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$7.49
Change2.32%
Shares Out58.91M
Market Cap$440.02M
52W Range10.52 - 34.48
Beta0.13
P/E-6.75
P/S0.00
P/B4.06
P/FCF-51.23
EV/Sales0.00
EV/EBITDA-53.40
Price$7.49
Change2.32%
Shares Out58.91M
Market Cap$440.02M
52W Range10.52 - 34.48
Beta0.13
P/E-6.75
P/S0.00
P/B4.06
P/FCF-51.23
EV/Sales0.00
EV/EBITDA-53.40
EV/FCF-76.51
Earnings Yield-3.70%
FCF Yield-1.95%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.01
Current Ratio5.96
Quick Ratio5.96
Target$36.75
Target Upside390.65%
Target Median$38.00
Target Range26.00 - 45.00
Volume526.06K
Avg Volume673.78K
EPS Surprise-0.14
Investment DNA
How strong this company looks for long-term investors
43
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
68/100
Why this score▼
Manageable debt level · 0.01Healthy liquidity · 5.96Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 9 analyst votes · 2026-10-20
100/100
Bullish
Bullish
9
Hold
0
Bearish
0
Price Target
2026-06-26
Low
$26.00
Mean
$39.40
Median
$38.00
High
$50.00
🧾
No insider activity
No recent insider transactions available.